GlobeNewswire

Leading Insurer Enlists Corvil Security Analytics to Reduce Cyber Risk

Dela

Firm cites superior visibility into user and host activity as well as integration into broader cybersecurity ecosystem among differentiators in selecting Corvil

NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Corvil today announced one of America's most highly rated financial institutions, with more than $80 billion in assets under management, has implemented Corvil Security Analytics to deliver real-time network traffic visibility, user activity analysis and network forensics to provide more comprehensive cyber threat detection and faster incident response.  

For the security team within this financial services firm, ensuring the security and compliance of sensitive data about millions of online customers was a strategic priority.  With more than 80 percent of breaches[1] stemming from inadvertent or malicious insiders, cyber attacks have the potential to wreak financial, reputational and compliance havoc.  According to reports[2], the number of cyber attacks against financial services companies has risen by more than 80 percent in the last year.  

In recognizing risks posed by its increasingly complex digital operations and looking for greater visibility within the network perimeter, the firm sought to fortify its security fabric. Following a competitive selection process, Corvil was enlisted to help mitigate risks associated with evasive threats. Among these threats are those that can often hide deep within normal network communications and seemingly appropriate user behavior, such as that of the firm's workforce and thousands of remote representatives.  Providing granular insights and integrated workflows, Corvil enabled faster and more complete investigations and threat hunting, resulting in more effective and efficient end-to-end security operations.  

Deployed across multiple data centers, Corvil's continuous packet capture, analysis, threat-matching, prioritization, and alerting extended the scope of threat detection across the corporate network.  The security team gained uniquely granular and contextualized insights into user and threat activity which drastically minimized the manual effort required for forensic investigation.

Dan Kennedy, Corvil VP and GM, Americas, said: "Incomplete or shallow information about suspicious activity can often be worse than none at all, owing to the tremendous overhead on security teams who must determine whether a breach has occurred and the impact thereof.  We have seen how empowering security analysts, of all levels, with greater insight can reduce attacker dwell times and improve the productivity of even high caliber security teams such as this customer."  

Corvil delivered intelligent integration with other best-of-breed security tools, extending the firm's protection fabric from the perimeter, across the network, and into endpoints, enabling the firm to:

  • Operationalize the use of threat intelligence for faster breach detection
  • Streamline and unify file extraction, threat analysis, and perimeter response with a leading next generation firewall provider
  • Simplify tracking of attack indicators and processes across the network and within hosts with Carbon Black Cb Response
  • Deliver further correlation of events and faster investigation through bidirectional workflows with a leading machine data analytics SIEM platform

Corvil's combination of unique insight and integration was a key differentiator during the competitive selection process. It enabled faster, more comprehensive response and maximized the value of their security ecosystem.   

"The advanced persistent threat landscape coupled with heightened regulatory oversight and stakeholder demands for utmost assurances from those charged with handling their sensitive data have caused cybersecurity technology budgets to surge [3] ," said  David Murray, Corvil Chief Marketing and Business Development Officer. "However a disparate and siloed set of cybersecurity technologies introduces greater levels of complexity to already overburdened security teams.  Time and time again, customers and analysts tell us that solutions designed to participate in a wider security ecosystem of data collection, analytics and policy enforcement are intrinsically more valuable. This latest win demonstrates that our strategy to design interoperable, best-of-breed solutions addresses this pressing market demand."

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.

Learn more about Corvil: Corvil.com | Twitter | LinkedIn

Notes to the editor
[1] 81% of hacking-related breaches leveraged either stolen and/or weak passwords - 2017 Verizon DBIR. This means that 81% of attacks will come from hacker controlled machines inside the perimeter.
[2] https://www.professionaladviser.com/professional-adviser/news/3027071/fca-data-sees-financial-services-data-hacks-quadruple-in-2016-17
[3] According to the EY 20th Global Information Security Survey 2017-18, - 59% of respondents this year say their budgets increased over the last 12 months.                   

Contact information: 
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum